NCT01754116 - A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1265744 30 mg oral

GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal

DRUG

Midazolam 3 mg oral + GSK1265744 30mg oral

Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14

DRUG

GSK1265744 400 mg (200 nm)

A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)

DRUG

GSK1265744 400 mg (1 micro m)

A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)

DRUG

GSK1265744 400 mg (5 micro m)

A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)

Trial Locations (1)

GSK Investigational Site, Overland Park